CA2458872A1 - Human ubiquitin-conjugating enzyme - Google Patents
Human ubiquitin-conjugating enzyme Download PDFInfo
- Publication number
- CA2458872A1 CA2458872A1 CA002458872A CA2458872A CA2458872A1 CA 2458872 A1 CA2458872 A1 CA 2458872A1 CA 002458872 A CA002458872 A CA 002458872A CA 2458872 A CA2458872 A CA 2458872A CA 2458872 A1 CA2458872 A1 CA 2458872A1
- Authority
- CA
- Canada
- Prior art keywords
- conjugating enzyme
- human ubiquitin
- pharmaceutical composition
- antibody
- radioisotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Disclosed is a pharmaceutical composition for treating prostate cancer, the pharmaceutical composition comprising an antibody against human TMP-2 protein together with a pharmaceutically acceptable carrier. In one embodiment, the antibody is conjugated to a therapeutic moiety which can be a cytotoxic agent or a radioisotope.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2641565A CA2641565C (en) | 1996-03-19 | 1997-03-19 | Nel-related proteins type 1 and 2, and polynucleotides encoding them |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6341096 | 1996-03-19 | ||
JP63410/1996 | 1996-03-19 | ||
JP69163/1997 | 1997-03-05 | ||
JP06916397A JP3646191B2 (en) | 1996-03-19 | 1997-03-05 | Human gene |
CA002200371A CA2200371C (en) | 1996-03-19 | 1997-03-19 | Human npik gene |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002200371A Division CA2200371C (en) | 1996-03-19 | 1997-03-19 | Human npik gene |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2641565A Division CA2641565C (en) | 1996-03-19 | 1997-03-19 | Nel-related proteins type 1 and 2, and polynucleotides encoding them |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2458872A1 true CA2458872A1 (en) | 1997-09-19 |
CA2458872C CA2458872C (en) | 2009-05-19 |
Family
ID=32474726
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002458872A Expired - Fee Related CA2458872C (en) | 1996-03-19 | 1997-03-19 | Human ubiquitin-conjugating enzyme |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2458872C (en) |
-
1997
- 1997-03-19 CA CA002458872A patent/CA2458872C/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2458872C (en) | 2009-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0330201A3 (en) | Method of enhancing the effect of cytotoxic agents | |
WO1994004702A3 (en) | Improved detection and therapy of lesions with biotin/avidin conjugates | |
MXPA01011008A (en) | Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases. | |
EP0658111A4 (en) | Methods for enhancing drug delivery with modified saponins. | |
AU1656501A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
ATE245662T1 (en) | AVIDIN-BIOTIN IMMUNOCONJUGATES | |
AP9801392A0 (en) | Concentrated antibody preparation. | |
CA2124218A1 (en) | Cytotoxic drug therapy | |
IL129356A0 (en) | Conjugates useful in the treatment of prostate cancer | |
PT837684E (en) | PHARMACEUTICAL COMPOSITIONS BASED ON A DICLOFENAC AND THYOCOLCHOSIDE SALT | |
MY137303A (en) | Methods for treating proliferative diseases | |
HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
CA2135312A1 (en) | Use of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme a reductase as a modality in cancer therapy | |
WO2003045429A3 (en) | Anti-t cell immunotoxin fusion protein and its therapeutic use | |
GB9601640D0 (en) | Ligand directed enzyme prodrug therapy | |
AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents | |
WO1999021574A3 (en) | Enhancement of morphogen activity | |
AU4953693A (en) | Antibody/radioisotope conjugate for tumor diagnosis and/or therapy | |
CA2458872A1 (en) | Human ubiquitin-conjugating enzyme | |
AU2193797A (en) | Delivery of therapeutic agents to the prostate | |
ZA9810974B (en) | Conjugates useful in the treatment of prostate cancer | |
AU6901191A (en) | Pharmacologically active substance bpc, the process for its preparation and its use in the therapy | |
AU4452900A (en) | Compositions and methods for the therapy and diagnosis of prostate cancer | |
CA2297149A1 (en) | 13-deoxyanthracycline derivatives for treating cancer | |
AU3478600A (en) | Treatment of autoimmune diseases with american ginseng extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20160321 |